-
Niraparib regimen may slow cancer growth in prostate cancer subset
05 Jun 2025 12:16 GMT
… prednisone for patients with homologous recombination repair-altered metastatic castration-resistant prostate cancer … (mCRPC).
Adding niraparib to abiraterone acetate and prednisone … metastatic hormone-sensitive prostate cancer and homologous …
-
ASCO 25: J&J combo pill may see wider use in prostate cancer
04 Jun 2025 15:07 GMT
… with metastatic castration-sensitive prostate cancer (mCSPC) bearing … treat metastatic castration-resistant prostate cancer (mCRPC) with BRCA … plus prednisone compared to Zytiga and prednisone.
For … patients with metastatic prostate cancer at the time …
-
Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer
03 Jun 2025 16:02 GMT
… with metastatic castration-sensitive prostate cancer (mCSPC) with alterations … acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) … plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer. FDA …
-
Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer
03 Jun 2025 13:00 GMT
… patients with metastatic castration-sensitive prostate cancer (mCSPC) who had homologous … BRCA-mutated castration-resistant prostate cancer, based on findings from … Zytiga plus prednisone for metastatic castration-sensitive prostate cancer with homologous …
-
ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclear
03 Jun 2025 12:03 GMT
… with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson … prostate cancer (mCSPC) with homologous recombination repair (HRR), Akeega and prednisone … &J owns prostate cancer rights—and Zytiga. … to Zytiga and prednisone showed a progression …
-
CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology
30 May 2025 19:00 GMT
… with metastatic castration-resistant prostate cancer (mCRPC) with bone … metastatic castration-resistant prostate cancer (mCRPC) with … metastatic castration-resistant prostate cancer (mCRPC) and … abiraterone acetate plus prednisone/prednisolone compared …
-
Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC
04 Jun 2025 04:01 GMT
… ) plus abiraterone acetate (Zytiga) and prednisone (AAP) for patients with homologous … ) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC).
-
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes
22 May 2025 15:02 GMT
… primary treatments for prostate cancer, tumor characteristics, treatment … metastatic castration-resistant prostate cancer (mCRPC) patients … castration-resistant prostate cancer treated with … prostate cancer treated with Abiraterone acetate plus prednisone. …
-
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.
08 May 2025 07:01 GMT
… prednisone (AAP) versus placebo + AAP in patients with metastatic castration-resistant prostate cancer …
-
Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight
05 May 2025 17:00 GMT
… prostate cancer, including Metastatic Castration-Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer … with prednisone in 2004 … Prostate Cancer Market Assessment Non-metastatic Prostate Cancer (nmPC) Market Prostate cancer …
About
© 1995-2025